Erasca Inc

2
NAS:ERAS (USA)  
$ 2.97 +0.16 (+5.69%) 10:08 PM EST
At Loss
P/B:
1.56
Market Cap:
$ 808.91M
Enterprise V:
$ 566.16M
Volume:
5.13M
Avg Vol (2M):
2.98M
Trade In:
Volume:
5.13M
At Loss
Avg Vol (2M):
2.98M

Business Description

Description
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
Name Current Vs Industry Vs History
Cash-To-Debt 5.42
Equity-to-Asset 0.78
Debt-to-Equity 0.19
Debt-to-EBITDA -0.39
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 85.32
9-Day RSI 77.2
14-Day RSI 71.27
6-1 Month Momentum % 15.03
12-1 Month Momentum % -20.14

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.14
Quick Ratio 10.14
Cash Ratio 9.84

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -87.7
Shareholder Yield % -1.78

Financials (Next Earnings Date:2024-08-09 Est.)

ERAS's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ERAS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Erasca Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -0.83
Beta 1.16
Volatility % 76.52
14-Day RSI 71.27
14-Day ATR ($) 0.191105
20-Day SMA ($) 2.31325
12-1 Month Momentum % -20.14
52-Week Range ($) 1.51 - 3.1
Shares Outstanding (Mil) 272.82

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Erasca Inc Filings

Filing Date Document Date Form
No Filing Data

Erasca Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Erasca Inc Frequently Asked Questions

What is Erasca Inc(ERAS)'s stock price today?
The current price of ERAS is $2.97. The 52 week high of ERAS is $3.10 and 52 week low is $1.51.
When is next earnings date of Erasca Inc(ERAS)?
The next earnings date of Erasca Inc(ERAS) is 2024-08-09 Est..
Does Erasca Inc(ERAS) pay dividends? If so, how much?
Erasca Inc(ERAS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1